Reduction of homocysteine levels in coronary artery disease by low-dose folic acid combined with vitamins B6 and B12.

[1]  H. Blom,et al.  Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials , 1998, BMJ.

[2]  J. Witteman,et al.  Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. , 1998, Circulation.

[3]  J. Manson,et al.  Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. , 1998, JAMA.

[4]  S. Vollset,et al.  Homocysteine and cardiovascular disease , 1996 .

[5]  J. Loscalzo.  The oxidant stress of hyperhomocyst(e)inemia. , 1996, The Journal of clinical investigation.

[6]  D. Wilcken,et al.  Distribution in healthy and coronary populations of the methylenetetrahydrofolate reductase (MTHFR) C677T mutation. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[7]  N. Samani,et al.  Genetic analysis of thermolabile methylenetetrahydrofolate reductase as a risk factor for myocardial infarction. , 1996, QJM : monthly journal of the Association of Physicians.

[8]  K. Robinson,et al.  Homocysteine and coronary atherosclerosis. , 1996, Journal of the American College of Cardiology.

[9]  David P Miller,et al.  Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. , 1995, Circulation.

[10]  G. Omenn,et al.  A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. , 1995, JAMA.

[11]  R. Riezler,et al.  Effects of vitamin B12, folate, and vitamin B6 supplements in elderly people with normal serum vitamin concentrations , 1995, The Lancet.

[12]  A. Lindgren,et al.  Plasma homocysteine in acute myocardial infarction: homocysteine‐lowering effect of folic acid , 1995, Journal of internal medicine.

[13]  M. Secic,et al.  Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: sex differences and correlation with cobalamin and folate concentrations in healthy subjects. , 1994, Clinical chemistry.

[14]  H. Blom,et al.  Treatment of mild hyperhomocysteinemia in vascular disease patients. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[15]  P. Lundberg,et al.  Disordered methionine/homocysteine metabolism in premature vascular disease. Its occurrence, cofactor therapy, and enzymology. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[16]  M. Norusis,et al.  Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. , 1991, American journal of human genetics.

[17]  P. Nilsson-ehle,et al.  Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate. , 1990, Scandinavian journal of clinical and laboratory investigation.

[18]  P. Wilson,et al.  Plasma homocyst(e)ine levels in men with premature coronary artery disease. , 1990, Journal of the American College of Cardiology.

[19]  B. Norrving,et al.  Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. , 1990, Atherosclerosis.

[20]  A. Hofman,et al.  Low vitamin B6 status in patients with acute myocardial infarction. , 1989, The American journal of cardiology.

[21]  J. Jeppsson,et al.  Folic acid--an innocuous means to reduce plasma homocysteine. , 1988, Scandinavian journal of clinical and laboratory investigation.

[22]  Vernon,et al.  Radioenzymatic assay for direct measurement of plasma pyridoxal 5'-phosphate. , 1983, Clinical chemistry.

[23]  D. Wilcken,et al.  The pathogenesis of coronary artery disease. A possible role for methionine metabolism. , 1976, The Journal of clinical investigation.

[24]  A. Doscherholmen,et al.  A dual mechanism of vitamin B12 plasma absorption. , 1957, The Journal of clinical investigation.

[25]  Soo-Sang Kang,et al.  Thermolabile Methylenetetrahydrofolate Reductase , 1997 .

[26]  P. Frosst,et al.  Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. , 1996, American journal of human genetics.

[27]  H. Blom,et al.  Thermolabile 5,10-methylenetetrahydrofolate reductase as a cause of mild hyperhomocysteinemia. , 1995, American journal of human genetics.

[28]  W. Vermaak,et al.  Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. , 1993, The American journal of clinical nutrition.

[29]  V. Kakkar,et al.  Pyridoxal 5'-phosphate--a new physiological inhibitor of blood coagulation and platelet function. , 1979, Biochemical pharmacology.